Loading…

Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

Tumor immunogenicity is driven by various genomic and transcriptomic factors but the association with the overall status of methylation aberrancy is not well established. We analyzed The Cancer Genome Atlas pan-cancer database to investigate whether the overall methylation aberrancy links to the imm...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2021-06, Vol.70 (6), p.1605-1617
Main Authors: Park, Changhee, Jeong, Kyeonghun, Park, Joon-Hyeong, Jung, Sohee, Bae, Jeong Mo, Kim, Kwangsoo, Ock, Chan-Young, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Jeon, Yoon Kyung, Lee, Se-Hoon, Lee, Ju-Seog, Kim, Dong-Wan, Kang, Gyeong Hoon, Chung, Doo Hyun, Heo, Dae Seog
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor immunogenicity is driven by various genomic and transcriptomic factors but the association with the overall status of methylation aberrancy is not well established. We analyzed The Cancer Genome Atlas pan-cancer database to investigate whether the overall methylation aberrancy links to the immune evasion of tumor. We created the definitions of hypermethylation burden, hypomethylation burden and methylation burden to establish the values that represent the degree of methylation aberrancy from human methylation 450 K array data. Both hypermethylation burden and hypomethylation burden significantly correlated with global methylation level as well as methylation subtypes defined in previous literatures. Then we evaluated whether methylation burden correlates with tumor immunogenicity and found that methylation burden showed a significant negative correlation with cytolytic activity score, which represent cytotoxic T cell activity, in pan-cancer (Spearman rho = − 0.37, p  
ISSN:0340-7004
1432-0851
DOI:10.1007/s00262-020-02796-1